Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reissued by equities researchers at Piper Jaffray Companies in a research note issued to investors on Sunday. They presently have a $14.00 target price on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target suggests a potential upside of 0.57% from the company’s previous close.

A number of other brokerages have also issued reports on VRX. Vetr lowered shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 price objective for the company. in a report on Monday, May 22nd. Barclays PLC reaffirmed a “hold” rating and set a $20.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, May 23rd. ValuEngine lowered shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Canaccord Genuity set a $14.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Thursday, June 8th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $15.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, June 9th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $17.62.

Valeant Pharmaceuticals International (VRX) opened at 13.92 on Friday. The stock’s market cap is $4.85 billion. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $27.84. The company’s 50-day moving average is $14.39 and its 200 day moving average is $13.19.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The company had revenue of $2.23 billion for the quarter, compared to analysts’ expectations of $2.23 billion. During the same quarter last year, the business earned ($0.88) EPS. The firm’s revenue was down 7.7% compared to the same quarter last year. On average, analysts expect that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals International’s (VRX) Sell Rating Reiterated at Piper Jaffray Companies” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/17/valeant-pharmaceuticals-internationals-vrx-sell-rating-reiterated-at-piper-jaffray-companies.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De bought 10,000 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was acquired at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 5.87% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Gruss & Co. Inc. bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth $104,000. Harbor Advisors LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth $110,000. WMS Partners LLC bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth $116,000. PNC Financial Services Group Inc. lifted its position in shares of Valeant Pharmaceuticals International by 33.7% during the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock worth $121,000 after purchasing an additional 2,763 shares during the last quarter. Finally, Baird Financial Group Inc. bought a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth $127,000. Institutional investors and hedge funds own 50.49% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.